Company intelligence / Profile preview
BioMarin Pharmaceutical Inc.
San Rafael, California, United Statesbiomarin.com ↗
- Ownership
- Public · BMRN
- Employees
- ~3401
- Development stage
- Other
01
Overview
BioMarin has developed and commercialized eight therapies for rare genetic diseases, with a focus on enzyme replacement therapies. They were the first company to provide therapeutics for mucopolysaccharidosis type I and phenylketonuria. Their products include Naglazyme, Aldurazyme, Kuvan, Voxzogo, Palynnziq, and BRINEURA.
- Therapeutic areas
- HematologyRare DiseasesNeurologyMetabolic Disorders
- Modalities
- Enzyme replacement therapies (ERTs)RNA-targeting medicines
- Industry
- Biotech
02
Drug pipeline
28 assets27 more assets in the full pipeline.
03
Partnerships
CAMP4 Therapeutics Corp (2024)Spruce Biosciences (2025)Genzyme Corporation (commercialization partner for Aldurazyme)
04
Financials
- Market cap
- $10.9B
- Total revenue
- $3.2B
- Enterprise value
- $14.3B
Beyond the preview
Go deeper on BioMarin Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioMarin Pharmaceutical Inc..